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While animal experiments have contributed much to our understanding of the mechanisms of Alzheimer’s disease (AD), their
value in predicting the eﬀectiveness of treatment strategies in clinical trials has remained controversial. The disparity between
the results obtained in animal models and clinical trials may in part be explained by limitations of the models and species-
speciﬁc diﬀerences. We propose that one trial passive avoidance in the day-old chick is a useful system to study AD because of
the close sequence homologies of chick and human amyloid precursor protein (APP). In the chick, APP is essential for memory
consolidation, and disrupting its synthesis or structure results in amnesia. RER, a tripeptide sequence corresponding to part of the
growth domain of APP, can restore memory loss and act as a cognitive enhancer. We suggest that RER and its homologues may
form the basis for potential pharmacological protection against memory loss in AD.
1.Introduction
At ﬁrst, the day-old chick does not seem a likely model
system in which to study the molecular processes involved in
a degenerative disease that primarily aﬀects brain function
in ageing humans. Before proceeding to argue the case
for including the chick amongst such models, however, we
should consider more carefully what we mean by, and expect
from, an “animal model” of a human disease.
Whatdoesonewantfromananimalmodel?Byananimal
model we mean a nonhuman organism that displays some
or all of the features of the human condition we wish to
understand. These may include some or all of the genetic,
molecular, physiological, anatomical, or behavioural features
of the human condition or acceptable analogues thereof. To
be of utility, such an organism must be readily amenable to
experimental manipulation in one or more of these biologi-
cal/behavioural levels. As the manifestation of the disease or
disorder is likely to be species-typical, especially when we are
dealingwithneurologicalorpsychiatricdiagnoses,inferences
astotherelevanceofanyanimalanaloguearealwaysgoingto
be problematic, as much of the literature on animal models
of depression and schizophrenia has demonstrated [1–5].
Alzheimer’s disease (AD) manifests itself in humans in
terms of behaviour—initially memory loss and confusion,
with progressive decline in other faculties. Neurologically,
there is accumulation of amyloid plaques and tangles, neu-
ronal death, notably of cholinergic cells in the hippocampus,
and brain shrinkage [6–9]. However, there is no known
naturally occurring animal equivalent of these features either
behaviourally or neurologically, apart from some partial
resemblances such as plaque accumulation in aged captive
apes. Thus, animal models have been directed towards
mimicking the neurological and/or biochemical features
of the disease, primarily in rodents, including transgenics,
and examining the behavioural consequences in terms of
impaired performance on standard memory tasks [10–12].
2. Choice of Task
The measure of neurological deﬁcit commonly chosen as
an indicator of an animal model’s relevance for AD is an
impairment in learning or memory retention in a standard
task. Such impairment is taken as analogous to, or better,
homologous with, that in human memory in conditions2 International Journal of Alzheimer’s Disease
such as AD. Standard laboratory tasks may be aversive or
appetitive, single or multiple trial. For rodents, they include
passive avoidance and fear conditioning (both single trial)
and versions of the Morris water maze (multiple trial). The
merit of one trial tasks is that they are sharply timed; the
brevity of the training trial allows for a separation of events
surrounding the training experience from the processes that
occur during memory consolidation. However, single trial
learning is not typical of learning in general, because many
instances of animal and human learning are based on the
acquisition of experience in a number of repeated trials,
involving processes such as generalisation, categorisation,
and discrimination. Furthermore, the memory expressed in
such animal models is procedural rather than declarative,
and procedural memory is the last, not the ﬁrst, to be lost
during the degeneration typical of the progression of AD.
While it is a necessary assumption for such studies that the
biochemical and pharmacological processes explored in the
context of animal memory have their parallels in the human
case, the repeated failure of agents which act as cognitive
enhancers in well-controlled animal experiments to aﬀect
human cognition in clinical trials is a salutary warning that
the assumption remains-just that.
3. The APP andAD
The amyloid precursor protein (APP) is a multifunctional
transmembrane glycoprotein involved in diverse and oppos-
ing cellular functions such as: synapse formation and main-
tenance [13–16], memory formation [17–23], regulation of
transcription, and neurotoxicity [13, 14]. It is extensively
processed posttranslationally by speciﬁc proteolytic cleavage
[13–15]. Like APP, the APP-derived fragments initiate or
execute a variety of cellular functions. Most of the evidence
that APP is implicated in memory consolidation is based on
the eﬀects of intracerebral or intraventricular injections of
exogenous APP, its proteolytic fragments, or antibodies and
antisense oligodeoxynucleotides. For example, smaller solu-
ble fragments of β-amyloid (Aβ) and structurally mimetic
nonpeptidic substances injected centrally antagonise the
binding of Aβ protein and produce amnesia [24]a sw e l la sa
decrease of K+-evoked acetylcholine release from hippocam-
pus [25, 26]. Centrally administered amyloid β peptides
(Aβ) impair retention in the Y-maze, passive avoidance and
place-learning in the water maze [26] and cause amnesia for
footshock active avoidance in mice [24]. Multiple bilateral
injections of Aβ1−40 into the dorsal hippocampus produce
performance decrements in short-term working memory
[27]. In contrast to the eﬀects of Aβ, the secreted form
of APP (sAPP) is neurotrophic and neuroprotective and
when administered intracerebroventricularly, shows potent
memory-enhancing eﬀects [26]; amongst other eﬀects it
prevents the learning deﬁcits induced by scopolamine in
an object recognition task and improves spatial recognition
memory [28–30].
APP is generally accepted to be directly involved in AD
and consequently has been extensively studied in a number
of diﬀerent mammalian and nonmammalian systems [13,
14]. Thus, attention has been focussed on enzymes such
as the alpha, beta, and gamma secretases associated with
the misprocessing of APP leading to accumulation of senile
plaques and methods for clearing or diminishing plaque
load. Animal models for AD such as mice transgenic for
the mutant forms of human APP are therefore in principle
directed towards any of these processes and events [11].
However, a major weakness of such studies, although very
understandable in the earlier days of AD research, has been
that the striking appearance of the plaques and the early
death of cholinergic cells has focussed excessive attention
on these end-products of the biochemical chain of events
leading to the disease, on the assumption that they are
both proximal causes of the condition and likely therapeutic
targets. An alternative hypothesis would be that the primary
lesion in the disease is the disruption of neural processes
that require the normal functioning of APP and are essential
for cognitive functions such as memory. It is towards this
hypothesis that our studies in the chick have proceeded,
and which in turn has resulted in uncovering a molecular
mechanism that could be of therapeutic signiﬁcance.
4.AvianAPP
Although birds and mammals diverged about 270 million
yearsago,andconsequentlyareverydiﬀerentinmorphology,
behaviour, lifespan, and in the age-dependent repression of a
broad-spectrum of neuronal genes, the chick may be a better
experimental model to study APP than mice because its APP
gene sequence and the enzymatic machinery for processing
APP are almost identical to that of humans and closer than
those in mice [31–38].
Chicken APP expression parallels mammalian APP
expression both temporally and topographically. Further-
more, the chick embryo expresses the genes that encode
the main proteases implicated in the production of APP,
including BACE-1, BACE-2, presenilin-1, presenilin-2, and
nicastrin as well as Neprilysin, the main Aβ-degrading
enzyme, and ADAM-17, a protease implicated in the non-
amyloidogenic processing of APP. Importantly, the level of
the APP gene expression is related to the strength of learning
in day-old chicks [19]. That makes the chick a useful natural
model in which to study the cell biology and functions of
APP and a potential “assay system” for drugs that regulate
APP processing.
The degree of evolutionary conservation of APP is very
high. The chick APP gene sequence, similar to that of the
mouse, has 93% amino acid identity and 96% similarity with
the human sequence (Figure 1). However, it is important
to stress that avian Aβ has 100% sequence similarity with
the human Aβ sequence in contrast to rodent Aβ which
is lacking residues Arg, Tyr, and His in the Aβ domain,
shown to be crucial for amyloidogenesis. In addition, the
rodent 5 upstream regulatory region of the APP gene is
only 82% homologous to the corresponding region of the
human APP gene [39]. These diﬀerences may be functionally
related to the fact that Aβ plaques do not accumulate in aged
memory impaired rodents. Another important diﬀerence
between rodents and humans is related to the sequence of
the last 101 C-terminal amino acids of the human APPInternational Journal of Alzheimer’s Disease 3
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Figure 1: Alignment of the amino acid sequences of human, mouse, and chick APP. The numbering refers to the human APP sequence. The
RERMS sequence is in gray. Amino acid sequences of Aβ domain are underlined. Residues implicated in amyloidogenesis are indicated in
bold. The human (P05067), chicken (Q9DGJ7) and mouse (P12023) APP sequences were obtained from the EMBL database (CLUSTAL
2.0.12 multiple sequence alignment).4 International Journal of Alzheimer’s Disease
sequence (corresponding to the Aβ, transmembrane and
intracytoplasmic domains). In contrast to mouse and rat,
chick and human sequence are identical. That makes the
chick a useful natural model in which to study regulation of
APP gene expression and the amyloidogenic characteristics
of Aβ.
In contrast to many transgenic models wild type
heterozygous chicks do not carry a burden of genetic
background which might be a possible confounding factor
with regard to crucial aspects of AD [40, 41]. Although
sophisticated and precise molecular genetic tools are applied
to transgenic animals in order to study the pathophysiology
of AD [11, 42, 43], animal performance in the behavioural
tests used to assess learning and memory is often aﬀected
by variables apparently unrelated to memory function, as
shown in an extensive study analysing data from 3003
mice tested in the Morris water maze [44]. This meta-
analysis showed that genetic background and environmental
diﬀerences between laboratories in rearing and handling
procedures alone can produce suﬃcient variation to span the
range of most, if not all, behavioural variables and can thus
easily mask or fake mutational eﬀects. In addition, disparity
attributable to evolutionary divergence between humans and
rodents, brings about another type of problem: the strong
but incomplete homology between human and mouse APP
sequences and the weaker but still considerable homology
between APP and APP-like protein (APLP2), compromise
accurate measurements of total APP transcript levels in
humanised APP transgenic mice and make assessment of
the neuropathogenic potential of human APP gene products
rather diﬃcult [42, 45, 46].
5. The Chick asan Animal Model
for the Study of Memory
Our route towards research on AD led through our lab’s
interest, over many years, in the molecular mechanisms
involved in memory storage, on which we have worked
extensively with the young chick. The suitability of the chick
as a model system for such studies is well documented.
Chicks are precocial birds, and need actively to explore and
learn about their environment from the moment they hatch.
Thus, they learn very rapidly to identify their mother on
the basis of visual, olfactory and auditory cues (imprinting),
to distinguish edible from inedible or distasteful food, and
to navigate complex routes. Training paradigms that exploit
these species-speciﬁc tasks work with the grain of the
animal’s biology, and because such learning is a signiﬁcant
event in the young chick’s life the experiences involved
may be expected to result in readily measurable brain
changes. Chicks have large and well-developed brains and
soft unossiﬁed skulls, making localised cerebral injections
of drugs easy without the use of implanted cannulae or
anaesthesia. The virtual lack of any blood-brain barrier in
these young animals also ensures rapid entry into the brain
of peripherally injected agents (for review see [47]).
The training task that we employ is one trial passive
avoidance, in which chicks learn to avoid pecking at a
small bead coated in the bitter, distasteful, but nontoxic
methylanthranilate (MeA). The task has the merits of being
rapid and sharply timed (chicks peck a bead within 10
seconds) and as many as 60 chicks can be trained in a
single session. Table 1 compares this chick task with those
commonly used in rodents. In the standard version of the
task in our lab, day-old chicks are held in pairs in small
pens, pretrained by being oﬀe r e das m a l ld ryw h i t eb e a d ,a n d
those that peck trained with a larger (4mmdia) chrome or
colouredbeadcoatedwithMeA.Chicksthatpecksuchabead
show a disgust reaction (backing away, shaking their heads
and wiping their bills) and will avoid a similar but dry bead
for at least 48 hours subsequently. However, they continue to
discriminate, as shown by pecking at control beads of other
colours. Chicks trained on the bitter bead are matched with
controls which have pecked at a water-coated or dry bead,
and which peck the dry bead on test. Generally some 80%
of chicks in any hatch group can be successfully trained and
tested on this protocol. Each chick is usually trained and
tested only once. Because the pecking response requires a
positive, accurate act by the bird, it also controls for eﬀects
on attentional, visual, and motor processes [47, 48].
The training task has two variants: strong, and weak. In
the strong version, the aversive substance used to coat the
beadsis100%MeAanditproduceshighandpersisting levels
of avoidance. However, if the MeA is diluted to 10%, the
high level of avoidance for the training bead persists only up
8 hours; long term memories are not formed. In its strong
form, the task can be used to identify the molecular cascade
involved in memory formation and the interventions that
impair consolidation; in its weak form the task can be used
to explore potential memory enhancing agents.
These features make the young chick a highly suitable
model for the analysis of the biochemical (and in our hands
morphological and physiological) correlates of memory
consolidation. Table 1 compares the passive avoidance task
in the chick with commonly used tasks in the mouse.
6. The Biochemical Cascadeof Memory
Consolidation in the Chick
Over the past decades a combination of correlative and
interventive experimental strategies has enabled us to iden-
tify a biochemical cascade that is associated with memory
consolidation in the minutes to hours following training.
These have been fully reviewed elsewhere [47]s oo n l ya
brief summary will be given here. In the minutes following
training on this task, there is upregulation of N-methyl-
D-aspartate receptor activity, phosphorylation of the presy-
naptic membrane protein B50, and genomic activation of
the immediate early genes c-fos and c-jun. During the next
hours after training, increased incorporation of fucose into
brain glycoproteins occurs. During this time, memory for
the passive avoidance task can be impaired by inhibitors
of protein and glycoprotein synthesis injected around the
time of training. Two regions of the chick brain are involved
speciﬁcally in the biochemical responses to the learning
experience. These are the intermediate medial mesopalliumInternational Journal of Alzheimer’s Disease 5
Table 1: Comparison of training tasks in chicks and mice.
Chicks Mice
Training paradigm Passive avoidance
Passive avoidance
Fear conditioning
Water maze (multiple trials)
Timing 10 secends training time
Passive avoidance - Brief
Fear conditioning - Brief
Water maze - multiple trials
Suitable for biochemical analysis Yes
Passive avoidance - yes
Fear conditioning - yes
Water maze - unsuitable
Sex
Natural distribution of males and females
in the hatch. (Sex determined post hoc by
inspection of gonads)
Generally males only
Group size Large (20 chicks/group) Small
Intracranial injections Anaesthesia not required Anaesthesia required
BBB Not fully developed Fully developed
Genome Sequenced in 2004 Sequenced in 2002
Transgenic model No Yes, many (for review see
Crews et al., 2010; [11])
(IMMP), an association “cortical” area, and the medial
striatum (MS), a basal ganglia homologue. The chick brain
is strongly lateralized and many, but not all, of the molecular
events we observe are conﬁned to the left IMMP.
All these events depend on de novo protein synthesis and
insertion of a variety of proteins, especially glycoproteins,
into pre- and postsynaptic membranes. Cell adhesion or
cell recognition molecules constitute a major group amongst
these glycoproteins. They are expressed both pre- and
post-synaptically and involved in the process that allows
information about synaptic activity to be simultaneously
communicated to both side of the synapse. Our early work
identiﬁed two such adhesion molecule, L1 and NCAM,
which are recruited into this cascade of cellular events
at diﬀerent periods posttraining. Injection of inhibitors
of protein and glycoprotein synthesis (anisomycin and 2-
deoxy-galactose resp.) at times corresponds to these periods
of recruitment (Figure 2) result in amnesia for the task
[47].
This and related data on the eﬀects of application of
protein synthesis inhibitors on memory retention led us
to propose that there were two waves of protein synthesis
occurring following a learning experience, the ﬁrst within
an hour of the experience and involving the synthesis of
proteins expressed by immediate early genes, and the second,
some 4–6 hours later, involving structural proteins such as
the adhesion molecules. Both are necessary for consolidation
of long-term memory.
7. APP andMemory Consolidation in the Chick
APP is an important member of the family of cell adhesion
molecules, and having identiﬁed a role for NCAM and L1
[51–53] in the consolidation cascade, it seemed logical to
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Figure 2: Two time-windows when protein synthesis is sensitive
to inhibitors of protein synthesis, such as anisomycin (ANI) and
glycoprotein synthesis, such as 2-d-Galactose (2-d-Gal).
explore the role of APP itself. Chick APP cross-reacts with
the mouse monoclonal antibody raised against human APP.
Therefore, we tested the eﬀect of anti-APP antibody on
memory. The residence time for the anti-APP corresponds
to the relatively rapid turnover time for membrane-bound
APP. When injected pre-training, anti-APP did not interfere
with the chicks pecking and learning the avoidance task;
however, it did result in amnesia in birds tested 30 minutes
later. Amnesia persisted for at least the subsequent 24 hours
and was not apparent if the antibody was injected just
posttraining or 5.5 hours after training [17, 49].
This ﬁnding indicated that APP might be required
at an early phase and not continually during memory
consolidation. Given that blocking APP function by use
of speciﬁc antibodies outside of a speciﬁc time window6 International Journal of Alzheimer’s Disease
Table 2: Eﬀect of anti-APP and APP antisense on memory retention.
Time of injection Memory retention
(% Avoidance) Time of injection Memory retention
(% Avoidance)
Control (Saline,
non-immune sera) 30 minutes pre-training 78–95 5.5 hours Posttraining 78–95
Anti APP 30 minutes pre training 28–35∗∗ 5.5 hours Posttraining 78–95
Control (SC) 6 hours pre-training 78–95 30 minutes pre-training 78–95
AS 6 hours pre-training 32–37∗ 30 minutes pre-training 7 8–95
N = 18–25; ∗P <. 05; ∗∗P <. 01.
Anti APP: monoclonal human antibody mAb22C11 [17]; AS: 16-mer end-protected phosphodiester oligodeoxynucleotide, 5  C X CG A GG A CT G AX C CA
3 , designed to correspond to the transcription start sites −146 and AUG1786 of the βAPP mRNA, immediately upstream of a ribozyme binding site [17];
SC: Scrambled AS sequence [17]; For further details see [18, 49, 50].
2μm
(a) (b)
5μm
(c)
Figure 3: RER binding detected on chick, human and mouse neuronal cells. Speciﬁc binding of the biotinylated RER (arrows) to chick (a),
human (b) and mouse neuronal (c) cell. Location of the chick neuronal cells is in the IMMP area; Human and mouse neuronal cells are
located in the CA1 are in hippocampus.
was without eﬀect, we compromised APP gene expression
using antisense oligodeoxynucleotides (AS) designed to
correspond to the −146 and to AUG1786 transcription
start site of APP [17]. The antisense oligodeoxynucleotides
(AS ODNs) were injected intracerebrally at 6 hours or 30
minutespre-trainingandchicksweretestedatdiﬀerenttimes
posttraining. Injection at 6 hours pre-training was aimed
to suppress APP synthesis during the ﬁrst wave of protein
synthesiswhiletheinjectionmadeat30minutespre-training
wasaimedatthesecondwave(Table 2).Thus,inbothgroups
the AS was present for 6 hours before training. Controls were
treated with scrambled (SC) ODNs or saline and trained and
tested as the AS ODNs treated groups.
The results showed that APP-antisense both decreased
APP gene expression and aﬀected memory formation. The
time-windowofonsetofamnesiarelativetotimeofinjection
of ODNs and to time of training conﬁrmed our previous
ﬁnding that APP exerts its function during an early phase
of memory formation and appears to be a necessary
factor in the biochemical cascade involved in the transition
between short- and long-term memory. Our ﬁndings on the
importance of APP in learning were supported by reports
[19] that APP gene expression in the young chick is related
to the strength of memory retention for an imprinting
task.
8. APP-RelatedPeptides asa Tool to
Study Memory
Studies conducted on the physiological activity of APP [54–
58] resulted in the identiﬁcation of a small stretch of amino
acids containing the RERMS sequence C-terminal to the KPI
insertion site of sAPP-695 as the active domain responsible
for growth promotion and neurite extension, neuronal sur-
vival, and for sAPP’s ability to interfere with the deleterious
eﬀects of Aβ on neurons. A synthetic peptide homologous
to the RERMS sequence, APP 328–332, was identiﬁed as the
shortest active peptide to exhibit trophic activity through
cell-surface binding and induction of inositol polyphosphate
accumulation. Such observations suggested that the RERMS
peptidemightsubstituteforsAPPduringmemoryformation
and thereby reverse or protect against the blockade resulting
from antibody or antisense.
We ﬁrst assessed the eﬀects of RERMS on memory
in chicks rendered amnesic by APP-antisense and APP-
antibody treatment [17, 49]. In the series of experiments
which followed, we studied the time window in which
injection of RERMS might aﬀect amnesia and showed that
if injected either before or just after training on the task,
the pepide protected against the memory loss. As a control
for the behavioural eﬀect of RERMS, we used the reversedInternational Journal of Alzheimer’s Disease 7
N N N
O
O
O
O HO
O
NH NH H2N H2N
HN HN
H
H
H
NH2
N N N
O
O
O
O HO
O
NH NH H2N H2N
HN HN
H
H
H
NH2
N N N
O
O
O
O HO
O
NH NH H2N H2N
HN HN
H
H
H
NH2
N N N
O
O
O
O HO
O
NH NH H2N H2N
HN HN
H
H
H
NH2
N N N
O
O
O
O
RER
REr ReR
HO
O
NH NH H2N H2N
HN HN
H
H
H
NH2
rER
rer
Figure 4: Structure of D/L tripeptides included in the study.
peptide sequence SMRER, but to our surprise SMRER was as
eﬀective in relieving the memory block as RERMS. However,
ad i ﬀerent control peptide, RSAER, was without eﬀect. Anal-
ysis of these experiments led to two principal observations:
ﬁrst, that the APP-derived peptide might exert its action by
compensating for the low presence of APP. According to the
proposed amyloid hypothesis, the faulty processing of APP
and accumulation of the amyloid fragments might be one
of the factors leading to neurotoxicity. Therefore, we tested
whether the RERMS peptide might also have a potential
protective eﬀect against the memory deﬁcit induced by Aβ.
Amyloid-beta, injected into the IMMP bilaterally at a dose
of 2μg/hemisphere, 30 minutes prior to training, resulted in
amnesia for the task in chicks tested 24 hours subsequently.
However, administration of 1μg/hemisphere of RERMS 10
minutes after Aβ injection prevented the memory deﬁcit
caused by Aβ. Conversely, if the injection is delayed to 5.5
hours posttraining, there is no subsequent amnesia.
The second observation came from analysis of the amino
acidsequenceofthepeptidesusedinthisstudy[17,49].Both
the forward and reverse sequences contain the tripeptide
palindrome RER. The next step was therefore to investigate
the ability of RER to relieve memory block under the same
conditions used for testing RERMS. The RER tripeptide,
when injected around the time of training, showed the same
potential as the RERMS pentapeptide and rescued memory
in animals rendered amnesic by pretreatment with Aβ.W e
concluded that the RER sequence acts as a core domain of
the growth promoting region of APP in the chick because it
appears able to substitute for sAPP. The protection against
the amnestic eﬀects of Aβ may also result from RER’s ability
toinitiatereceptor-mediatedprocesses.Thisinterpretationis
strengthenedbytheevidencethatRERbindstotwoneuronal
cell membrane proteins, of ∼66 and 110kDa, respectively. In
experiments aimed at identifying speciﬁc neuronal binding
partners, using a combination of biotinylated tripeptide and
cell-speciﬁc antibodies, bound RER was localised in chick
andhumanbrainsections(Figure 3),suggestingthatitmight
alsobeactivein humans,andcouldplayanimportant rolein
the memory formation process which is deﬁcient in the early
stages of AD. Moreover, the distribution of biotinylated RER
binding suggested membrane binding. In the chick, binding
is displaced by longer peptides derived from APP’s external
domain, but not by Aβ, suggesting that RER competes with
s A P Pf o rap u t a t i v er e c e p t o r[ 17, 49].
To overcome the problem of the short half-life of RER
we protected it by N-acylation, and showed that Ac-RER
is as eﬀective as RER in protecting against memory loss.
More importantly, Ac-RER crosses the partially formed
blood brain barrier of the one-day old chicks, enabling the
peptide to be injected intraperitoneally [17]. The immediate
implication of these ﬁndings is that it is possible to introduce8 International Journal of Alzheimer’s Disease
Table 3: Summary of peptides and their eﬀects on memory reported in this study.
Peptide Injection route Eﬀective dose Rescue of amnesia induced with: Enhances
weak training
Crossing
BBB
t1/2 hour
Ic ip Icμg/brain Ipmg/kgbw Anti APP AS Aβ Up to
RERMS Y Y 4 20–25 Y Y Y Y Y 2
SMRER Y Y 4 20–25 Y Y Y Y Y 2
RSAER NN 4 / N N N N Y /
RER Y Y 4 20–25 Y Y Y Y Y /
Ac-RER Y Y 16 20–25 Y / Y Y Y 6
Ac-RRE NN 1 6 / / /N N / /
Ac-rER Y Y 16 20–25 Y / Y Y Y >12
Ac-REr NN 1 6 / N /N N / /
Ac-ReR NN 1 6 / N /N N / /
Ac-rer Y Y 16 20–25 N / N N / /
Y: yes, there is an eﬀe c to nm e m o ry;N :N o ,t h e r ei sn oe ﬀect on memory; Anti-APP: monoclonal antibody, clone mAb22C11 [17]; AS: 16-mer end-protected
phosphodiester oligodeoxynucleotide, 5  C X CG A GG A CT G AX C CA3  , designed to correspond to the transcription start sites −146 and AUG1786 of the
βAPP mRNA, immediately upstream of a ribozyme binding site [17]; Aβ: amyloid-beta. For further details see [18, 49, 50].
ab e h a v i o u r a l l ye ﬀective form of RER peripherally by N-
terminal acylation, hence protecting the peptide against
rapid degradation.
If the RER sequence acts as a substitute for sAPP than
the question to ask is whether it might act as a cognitive
enhancer in the weak version of the passive avoidance task
discussed above. The weak training protocol is an ideal
paradigm to test this hypothesis as memory for the task is
not retained beyond an early phase, presumably because the
mild aversant does not provide a suﬃcient signal for the
release of sAPP. Under these conditions, tripeptide injected
p e r i p h e r a l l yw a sa se ﬀective as memory enhancer as when
injected intracerebrally, meaning that even in the weak
training task, in the presence of the tripeptide peptide,
memory persists for at least 24 hours.
All our results point to the short APP-related peptides
used in our experiments as both powerful tools in studying
the structure and function of APP and as of potential
therapeutic interest in AD. We have therefore begun to
explore the eﬀectiveness of a number of compounds struc-
turally related to RER. Of particular interest have been
the optically isomeric D- or diasteromeric (D/L) forms of
the peptide, which are more resistant to proteolysis than
their L-equivalents. The diasteromeric forms have begun
lately to attract increasing interest as potential immunogens,
diagnostic and therapeutic agents [59].
Our results using diﬀerent D/L forms (shown in
Figure 4) demonstrated that substitution of C-terminal L-
argininewiththeD-isomeressentiallyabolishedthememory
retention-enhancing eﬀect of the peptide. This ﬁnding
pointed to the crucial role of C-terminal L-arginine, in its
normal L-conformation, in binding to the peptide’s putative
receptors.
Moreover, these experiments clearly show that Ac-rER
is a longer lasting and more stable form of the putative
memory enhancer than the RER. In addition, it is taken
up into the brain from peripheral administration, and is
active behaviourally for at least 12 hours following such
administration. The fact that there was no diﬀerence in the
magnitude of the eﬀect of the L- and L/D tripeptide on
behaviour suggested that they engage the same biochemical
processes [50]. These results are summarised in Table 3.
What is now required is to determine the identity of the
RER binding proteins, the speciﬁc second messenger systems
activated and the genes controlled by RER. Our currently
unpublished experiments go some way towards answering
these questions, which may be central to understanding
the peptide’s eﬀects both in memory enhancement and,
potentially, in neuroprotection.
9. Concluding Remarks
Although it remains important to demonstrate that the
peptide or its related structures is eﬀective in other learning
tasks and in mammals, we propose that the chick is a
useful animal model in which to study AD, and that Ac-
rER is a molecule which might form the basis for a potential
therapeutic agent in the early stages of AD. Even though
some speciﬁc details of protein-protein interactions can
vary between birds and human, the degree of functional
conservation seems to be of particular relevance for the
AD ﬁeld. This animal model, like many other natural
model-systems, often appears to suﬀer from publication
bias towards transgenic animal models, which may account
for substantial under-representation of avian model system
in the experimental literature related to neurodegenerative
d i s e a s e ss u c ha sA D .
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